DAM
PVLA

DLD Asset Management’s Palvella Therapeutics PVLA Stock Holding History

DLD Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-313
Closed -$85K – 102
2019
Q3 		$85K Buy
+313
New +$121K ﹤0.01% 79

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DLD Asset Management's PVLA Position: Q4 2019 in Review

DLD Asset Management sold out of Palvella Therapeutics (PVLA) in Q4 2019, closing a stake of 313 shares — an estimated $85K sold.

DLD Asset Management first reported a position in PVLA in Q3 2019 and held it in 1 quarter. The position peaked at $85K in Q3 2019. 97 funds tracked by Wall St. Rank hold PVLA as of Q4 2019.

  • DLD Asset Management reported no remaining Palvella Therapeutics position as of Q4 2019 after selling out during the quarter.
  • DLD Asset Management sold 313 Palvella Therapeutics shares in Q4 2019, an estimated $85K.
  • DLD Asset Management first reported a position in Palvella Therapeutics in Q3 2019 and held it in 1 quarter.
  • DLD Asset Management's Palvella Therapeutics position peaked at $85K in Q3 2019.
  • 97 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2019.

Based on DLD Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.